VYYRF (Voyageur Pharmaceuticals) 3-Year Share Buyback Ratio: -15.70% (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VYYRF Voyageur Pharmaceuticals Ltd VYYRF
28 GF Score
Price $0.12
! 6 Warning Signs
View Full Analysis

What is Voyageur Pharmaceuticals 3-Year Share Buyback Ratio?

Voyageur Pharmaceuticals VYYRF 28 3-Year Share Buyback Ratio is -15.70 as of May. 2026. GuruFocus rates VYYRF with a GF Score™ of 28/100. The stock has 6 warning signs investors should review. Among 646 Drug Manufacturers companies, Voyageur Pharmaceuticals ranks worse than 80.8% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Voyageur Pharmaceuticals's current 3-Year Share Buyback Ratio was -15.70%.

The historical rank and industry rank for Voyageur Pharmaceuticals's 3-Year Share Buyback Ratio or its related term are showing as below:

VYYRF' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -205.2   Med: -21.4   Max: 6.9
Current: -15.7

During the past 13 years, Voyageur Pharmaceuticals's highest 3-Year Share Buyback Ratio was 6.90%. The lowest was -205.20%. And the median was -21.40%.

VYYRF's 3-Year Share Buyback Ratio is ranked worse than
80.8% of 646 companies
in the Drug Manufacturers industry
Industry Median: -2.1 vs VYYRF: -15.70

Voyageur Pharmaceuticals (OTCPK:VYYRF) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Voyageur Pharmaceuticals 3-Year Share Buyback Ratio Related Terms


VYYRF vs ZTS: 3-Year Share Buyback Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Voyageur Pharmaceuticals's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Voyageur Pharmaceuticals 3-Year Share Buyback Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Voyageur Pharmaceuticals's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Voyageur Pharmaceuticals's 3-Year Share Buyback Ratio falls into.


VYYRF
28GF Score
Voyageur Pharmaceuticals Ltd VYYRF
3-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Voyageur Pharmaceuticals 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Share Buyback Ratio of -15.70 mean?
Voyageur Pharmaceuticals (VYYRF) has a 3-Year Share Buyback Ratio of -15.70 as of May. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Voyageur Pharmaceuticals and its competitors. According to the industry distribution chart, Voyageur Pharmaceuticals ranks #522 out of 646 companies in the Drug Manufacturers industry, placing it in the top 80.8%.
Is Voyageur Pharmaceuticals' 3-Year Share Buyback Ratio too high?
Voyageur Pharmaceuticals' current 3-Year Share Buyback Ratio is -15.70. Based on the distribution chart, Voyageur Pharmaceuticals ranks #522 out of 646 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Voyageur Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Voyageur Pharmaceuticals' 3-Year Share Buyback Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Voyageur Pharmaceuticals ranks #522 out of 646 companies for 3-Year Share Buyback Ratio. This places Voyageur Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Voyageur Pharmaceuticals and its competitors. Voyageur Pharmaceuticals's current 3-Year Share Buyback Ratio is -15.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyageur Pharmaceuticals stock overvalued right now?
Voyageur Pharmaceuticals (VYYRF) has a current 3-Year Share Buyback Ratio of -15.70. The current 3-Year Share Buyback Ratio is -15.70. Voyageur Pharmaceuticals' overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Voyageur Pharmaceuticals (VYYRF), the current 3-Year Share Buyback Ratio is -15.70 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Voyageur Pharmaceuticals Business Description

Other Exchanges VM:Canada
Address 4103B Center Street NW, Calgary, AB, CAN, T2E 2Y6
Voyageur Pharmaceuticals Ltd is a Canadian development-stage pharmaceutical company developing and selling barium and iodine active pharmaceutical ingredients (API) and high-performance, cost-effective imaging contrast agents for medical radiology. Its product portfolio comprises SmoothX (a barium sulfate suspension), SmoothHD, SmoothLD (a low-density barium suspension solution), VisionHD (a high-density barium powder suspension), VisionLD, V-Gas, and others. Additionally, the company has interests in two mineral properties: Frances Creek and Jubilee Mountain, located in the province of British Columbia, Canada, and the ULI Project in the state of Utah, United States of America.
28GF Score

Get the complete analysis for VYYRF

3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.12
Price